MERCURY BIOPHARMACEUTICAL CORPORATI financial statements, including revenue, expenses, profit, and loss

The total revenue of 6932 for the last semiannual is 4.72 M TWD, and it's 356.63% higher compared to the previous semiannual. The net income of H1 24 is -18.30 M TWD.